JP2017522370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522370A5 JP2017522370A5 JP2017519999A JP2017519999A JP2017522370A5 JP 2017522370 A5 JP2017522370 A5 JP 2017522370A5 JP 2017519999 A JP2017519999 A JP 2017519999A JP 2017519999 A JP2017519999 A JP 2017519999A JP 2017522370 A5 JP2017522370 A5 JP 2017522370A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- disease
- hal
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 6
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000007371 Ataxin-3 Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 210000004081 cilia Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010054442 polyalanine Proteins 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306076.2 | 2014-07-02 | ||
| EP14306076 | 2014-07-02 | ||
| PCT/EP2015/065162 WO2016001390A1 (en) | 2014-07-02 | 2015-07-02 | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522370A JP2017522370A (ja) | 2017-08-10 |
| JP2017522370A5 true JP2017522370A5 (enExample) | 2019-01-24 |
| JP6621815B2 JP6621815B2 (ja) | 2019-12-18 |
Family
ID=51176304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519999A Expired - Fee Related JP6621815B2 (ja) | 2014-07-02 | 2015-07-02 | Ｏ−アルキル−ベンジリデングアニジン誘導体、及びミスフォールドタンパク質の蓄積と関連する障害の処置のための治療的使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10544093B2 (enExample) |
| EP (1) | EP3164391B1 (enExample) |
| JP (1) | JP6621815B2 (enExample) |
| KR (1) | KR20170027737A (enExample) |
| CN (1) | CN106488907B (enExample) |
| AU (1) | AU2015282901B2 (enExample) |
| CA (1) | CA2951186A1 (enExample) |
| DK (1) | DK3164391T3 (enExample) |
| ES (1) | ES2749657T3 (enExample) |
| HR (1) | HRP20191731T1 (enExample) |
| HU (1) | HUE046660T2 (enExample) |
| IL (1) | IL249485B (enExample) |
| MX (1) | MX2016016491A (enExample) |
| PL (1) | PL3164391T3 (enExample) |
| PT (1) | PT3164391T (enExample) |
| RS (1) | RS59400B1 (enExample) |
| RU (1) | RU2706002C2 (enExample) |
| SI (1) | SI3164391T1 (enExample) |
| WO (1) | WO2016001390A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3280405B1 (en) | 2015-04-08 | 2021-07-07 | United Kingdom Research and Innovation | Inhibitors and their uses |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| WO2019215470A1 (en) | 2018-05-09 | 2019-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies |
| JP2021529814A (ja) * | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
| US20240293343A1 (en) | 2023-02-13 | 2024-09-05 | Inflectis Bioscience | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3982020A (en) | 1970-03-17 | 1976-09-21 | Sandoz, Inc. | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| AU645799B2 (en) * | 1990-05-07 | 1994-01-27 | Novartis Ag | Hydrazones |
| SE9604348D0 (sv) * | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| US7071211B2 (en) | 2002-09-27 | 2006-07-04 | Bausch & Lomb Inc. | Small organic molecules that increase the activity of gelatinase a in ocular cells |
| KR20060088885A (ko) | 2003-09-25 | 2006-08-07 | 아카디아 파마슈티칼스 인코포레이티드 | 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법 |
| CN1875271A (zh) * | 2003-09-25 | 2006-12-06 | 阿卡蒂亚药品公司 | 用神经肽ff受体2激动剂治疗神经痛 |
| EP1908464A1 (en) | 2006-10-04 | 2008-04-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
| GB0623381D0 (en) * | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
| WO2011061340A1 (en) | 2009-11-23 | 2011-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity |
| AU2013223965C1 (en) | 2012-02-24 | 2018-01-04 | Universite De Strasbourg | Compositions and methods for the treatment of retinal degeneration |
| US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
-
2015
- 2015-07-02 HU HUE15733468A patent/HUE046660T2/hu unknown
- 2015-07-02 CN CN201580036468.9A patent/CN106488907B/zh not_active Expired - Fee Related
- 2015-07-02 WO PCT/EP2015/065162 patent/WO2016001390A1/en not_active Ceased
- 2015-07-02 AU AU2015282901A patent/AU2015282901B2/en not_active Ceased
- 2015-07-02 US US15/316,797 patent/US10544093B2/en not_active Expired - Fee Related
- 2015-07-02 MX MX2016016491A patent/MX2016016491A/es active IP Right Grant
- 2015-07-02 RS RSP20191318 patent/RS59400B1/sr unknown
- 2015-07-02 JP JP2017519999A patent/JP6621815B2/ja not_active Expired - Fee Related
- 2015-07-02 HR HRP20191731 patent/HRP20191731T1/hr unknown
- 2015-07-02 PT PT157334681T patent/PT3164391T/pt unknown
- 2015-07-02 PL PL15733468T patent/PL3164391T3/pl unknown
- 2015-07-02 EP EP15733468.1A patent/EP3164391B1/en active Active
- 2015-07-02 RU RU2016151411A patent/RU2706002C2/ru active
- 2015-07-02 ES ES15733468T patent/ES2749657T3/es active Active
- 2015-07-02 KR KR1020167036779A patent/KR20170027737A/ko not_active Ceased
- 2015-07-02 CA CA2951186A patent/CA2951186A1/en not_active Abandoned
- 2015-07-02 SI SI201530959T patent/SI3164391T1/sl unknown
- 2015-07-02 DK DK15733468.1T patent/DK3164391T3/da active
-
2016
- 2016-12-11 IL IL249485A patent/IL249485B/en active IP Right Grant
-
2019
- 2019-12-02 US US16/700,327 patent/US11084783B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019223182B2 (en) | Substituted pyrrolizine compounds as HBV replication inhibitors | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP6839104B2 (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| JP2015512951A5 (enExample) | ||
| HRP20191731T1 (hr) | O-alkil-benzilideneguanidinski derivati i terapijska upotreba za tretman poremećaja povezanih s akumulacijom pogrešno savijenih proteina | |
| US9102686B2 (en) | 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators | |
| HK1253029A1 (zh) | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 | |
| JP2020502092A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2019514876A5 (enExample) | ||
| JP2012528105A5 (enExample) | ||
| JP2015511958A5 (enExample) | ||
| JP2023547770A5 (enExample) | ||
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| JP5859454B2 (ja) | Ｍｋ２インヒビター | |
| JP2017538712A5 (enExample) | ||
| JP6967000B2 (ja) | セフェム系化合物、それらの生成および使用 | |
| JP2021516674A5 (enExample) | ||
| SA516370956B1 (ar) | مركب ثنائي الحلقات يحتوي على الكبريت | |
| JP2023550654A5 (enExample) | ||
| JP4885709B2 (ja) | ピリジニルアセトニトリル類 | |
| WO2021121420A1 (zh) | 苯并吡唑类化合物及其中间体、制备方法和应用 | |
| JP2017522383A5 (enExample) | ||
| JP2012012388A5 (enExample) | ||
| JP2014509297A5 (enExample) |